Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know

Taysha Gene Therapies (TSHA) is projected to report a Q2 2025 loss of $0.07 per share, representing a 22.2% year-over-year improvement, on expected revenues of $1.72 million, up 55%. Despite holding a Zacks Rank #2 (Buy), the company's Earnings ESP of -14.29% indicates that the Most Accurate Estimate is below the consensus, suggesting a recent bearish shift among analysts. This combination makes a definitive prediction of an earnings beat challenging, positioning TSHA as a less compelling candidate for a positive surprise.

Analysis

Taysha Gene Therapies (TSHA) is approaching its Q2 2025 earnings report with a mixed set of expectations. The consensus forecast is for significant fundamental improvement, projecting revenues of $1.72 million, a 55% year-over-year increase, and a narrower loss of $0.07 per share, which represents a 22.2% improvement from the prior year. However, despite this positive top-line and bottom-line outlook and a favorable Zacks Rank of #2 (Buy), near-term indicators suggest caution. The company's Earnings ESP is a negative 14.29%, indicating that the most recent analyst estimates are more bearish than the consensus. This negative reading, combined with a history of beating EPS estimates in only two of the last four quarters, makes it difficult to conclusively predict a positive surprise. The consensus EPS estimate has also remained unchanged over the last 30 days, suggesting a lack of recent upward revisions from the broader analyst community, which further tempers expectations for an earnings beat.

Key Decisions for Investors

• Given the conflicting signals of strong year-over-year growth forecasts but a negative Earnings ESP of -14.29%, investors should be prepared for potential stock volatility around the earnings release.
• It is prudent to weigh the long-term potential indicated by the 55% revenue growth forecast against the short-term risk of an earnings miss suggested by recent bearish analyst sentiment.
• Pay close attention to management's guidance and discussion of business conditions on the earnings call, as this will be critical for clarifying the outlook and will likely be a more significant driver of the stock's direction than the headline beat or miss itself.